New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by 
Sanofi licenses US rights to Pozen's cardiovascular disease prevention candidates; rights returned
Sep 2013
Executive Summary
Pozen Inc. (develops aspirin-based therapies for out-licensing) has granted Sanofi US exclusive rights to sell its PA8140 and PA32540, two tablets that each contain enteric-coated aspirin and the proton pump inhibitor omeprazole for the prevention of secondary cardiovascular diseases including coronary artery disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi licenses US rights to Pozen's cardiovascular disease prevention candidates; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice